Cyclo Therapeutics logs efficacy win in pivotal Niemann-Pick disease trial
Cyclo Therapeutics’ Trappsol Cyclo was able to induce clinical improvement in seven out of eight children with Neimann-Pick ...
Cyclo Therapeutics reports promising NPC1 treatment findings
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (NASDAQ:CYTH), a clinical-stage biotechnology firm with a market capitalization of $22.15 million, announced positive data from a sub-study of its pivotal ...
Le Lézard3 天
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPCtm ...
Cyclo Therapeutics, Inc. ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and ...
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC ...
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation ...
Investornewsbreaks Oragenics Inc. (NYSE American: OGEN) Chief Medical Officer To Speak At ...
Oragenics (NYSE American: OGEN) announced that its Chief Medical Officer, Dr. James P. Kelly, will be a featured panelist at the 12th Annual Brain He ...
Zevra Therapeutics price target raised to $21 from $20 at Guggenheim
Guggenheim raised the firm’s price target on Zevra Therapeutics (ZVRA) to $21 from $20 and keeps a Buy rating on the shares. The firm, which is ...